|
Recently most innovative therapies proposed for the treatment of retinal degeneration, gene therapies and stem cell therapies for example, have not had successful clinical studies leading to the marketing of new interventions for vision loss. This course will provide a review of the recent innovative therapies that have failed to come on the market with specific information of how the technology research and development including clinical studies and other FDA processes led to the therapies not being marketed for the blind and visually impaired population. There will be discussions of the processes to meet the vision restoration needs of individuals that are blind or visually impaired. |
